Patents by Inventor Norma S. Kenyon

Norma S. Kenyon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110065675
    Abstract: Azo dyes and suramin-related small molecules are effective in inhibiting the CD40/CD154 protein-protein interaction, an important co-stimulatory interaction involved in the activation of immune responses mediated by T- and B-cells. The compounds were found to be active as indicated by their IC50 values both in a cell-free binding assay and in the inhibition of CD154-induced B-cell proliferation assay. The compounds may be used as therapeutic compounds for treatment of diseases and disorders related to immune or inflammatory responses. Methods of inhibiting the CD40/CD154 protein-protein interaction and treating diseases and disorders related to immune or inflammatory responses are described.
    Type: Application
    Filed: May 5, 2009
    Publication date: March 17, 2011
    Applicant: University of Miami
    Inventors: Peter Buchwald, Emilio Margolles-Clark, Norma S. Kenyon, Camillo Ricordi
  • Publication number: 20030072754
    Abstract: Methods and compositions for inhibiting rejection of insulin-producing tissue in a graft recipient, as well as methods and compositions for prolonging graft survival or function; for reversing graft rejection or restoring function of an impaired graft; and, for inducing immunological tolerance to grafted, insulin-producing tissue. The present methods and compositions are suitable for treatment or prophylaxis of defects in metabolic control of blood glucose homeostasis, including defects manifested as diabetes mellitus (DM).
    Type: Application
    Filed: October 11, 2002
    Publication date: April 17, 2003
    Applicant: Biogen, Inc.
    Inventors: Norma S. Kenyon, Camillo Ricordi, David W. Thomas, Linda Burkly
  • Patent number: 6004743
    Abstract: A cell population or subpopulation enrichment procedure for separating undesired populations or subpopulations from a biological sample utilizing relatively heavy, dense particles and gravity sedimentation. The particles have one or more reactants bound thereto which are specific to and will bind with the selected population or subpopulation to be eliminated from the sample. The particles preferably are mixed with the sample by repeatedly causing the particles to settle through a substantial portion of the sample to bind to the selected population. The particles with the bound selected population to be eliminated then are allowed to preferentially settle in the sample and the supernatant including the enriched population or subpopulation is separated from the particles with the population to be eliminated bound thereto.
    Type: Grant
    Filed: December 10, 1997
    Date of Patent: December 21, 1999
    Inventors: Norma S. Kenyon, Thomas R. Russell, Camillo Ricordi, Robert K. Zwerner
  • Patent number: 5527713
    Abstract: The invention describes the use of novel aminodextran compounds containing about 5-20% by weight amine groups to bind a plurality of monoclonal antibodies. The resulting antibody-aminodextran compounds may be used to induce the activation and proliferation of selected mammalian cells. Specific examples are given using an anti-CD3 monoclonal antibody conjugated two aminodextrans containing about 5% and 16%, respectively, by weight amine groups as an agent for inducing the activation and proliferation of T cells.
    Type: Grant
    Filed: July 19, 1995
    Date of Patent: June 18, 1996
    Assignee: Coulter Corporation
    Inventors: Wade E. Bolton, John A. Maples, Olavi Siiman, Norma S. Kenyon, Cynthia G. Healy